Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Fludarabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention. Browse Fludarabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1453
Shown on this page
12
Current sort
Recently updated
Therapy scope
Fludarabine
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Fludarabine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 301–312 of 1,453 matching trials for Fludarabine.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 2 Interventional

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

NCT03121001
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ATG, fludarabine, cyclophosphamide, Total body irradiation, Stem cell infusion, Sirolimus, mycophenolate mofetil
Drug · Radiation · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
Biological · Drug
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

CD30 CAR for CD30+ NSGCT

NCT05634785
View directory record Official record
Conditions
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
Interventions
ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Active, not recruiting Phase 1 Interventional

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NCT01666080
View directory record Official record
Conditions
Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
Interventions
Busulfan, Fludarabine, Total body irradiation, Stem cell transplant, Keppra
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Phase 2 Interventional

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT05805605
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT04809766
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine, Bendamustine
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

NCT06996119
View directory record Official record
Conditions
Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Suspended Phase 1 Interventional

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

NCT03710421
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
CS1-CAR T Therapy, Cyclophosphamide, Fludarabine, Leukapheresis
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

NCT05653271
View directory record Official record
Conditions
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Active, not recruiting Phase 1 Interventional

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

NCT03241940
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 29, 2026, 4:21 AM EDT

About this Fludarabine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Fludarabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fludarabine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Fludarabine.